# Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

> **NCT03286738** · — · UNKNOWN · sponsor: **Joong Bae Ahn** · enrollment: 1800 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** FOLFIRI, target agent

## Key facts

- **NCT ID:** NCT03286738
- **Lead sponsor:** Joong Bae Ahn
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2021-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03286738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03286738, "Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03286738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*